Risk Factors That Increase Risk of Estrogen Receptor-Positive and -Negative Breast Cancer

Journal of the National Cancer Institute

Volumn 109, Issue 5, 2017, Pages

  Kerlikowske, Karla ^a,f   Gard, Charlotte C ^b   Tice, Jeffrey A ^a   Ziv, Elad ^a   Cummings, Steven R ^c   Miglioretti, Diana L ^d,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NEW MEXICO STATE UNIVERSITY   (United States)

^c CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CENTER FOR HEALTH STUDIES   (United States)

^f SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BODY MASS; BREAST BIOPSY; BREAST DENSITY; BREAST DISEASE; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RISK; COHORT ANALYSIS; DISEASE ASSOCIATION; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; ETHNICITY; FAMILY HISTORY; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; LOBULAR CARCINOMA IN SITU; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MENOPAUSE; MIDDLE AGED; OBESITY; POSTMENOPAUSE; PRIORITY JOURNAL; TUMOR BIOPSY; TUMOR INVASION; AFRICAN AMERICAN; AGE; BREAST TUMOR; CAUCASIAN; CHEMISTRY; ESTROGEN THERAPY; GENETICS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

ESTROGEN RECEPTOR;

ADULT; AFRICAN AMERICANS; AGE FACTORS; AGED; BODY MASS INDEX; BREAST DENSITY; BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; RISK FACTORS;

EID: 85021361132     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djw276     Document Type: Article

References (66)

1. Henderson L, Miglioretti D, Kerlikowske K, Wernli K, Sprague B, Lehman C. Breast cancer characteristics associated with digital versus screen-film mammography for screen-detected and interval cancers. AJR. 2015;205(3): 676-684.
2. Kirsh V, Chiarelli A, Edwards S, et al. Tumor characteristics associated with mammographic detection of breast cancer in the Ontario breast screening program. J Natl Cancer Inst. 2011;103(12):942-950.
3. Kerlikowske K, Hubbard R, Miglioretti D, et al. Comparative-effectiveness of digital vs film-screen mammography in community practice in the U.S. Ann Intern Med. 2011(8);155:493-502
4. Tice J, Miglioretti D, Li C, Vachon C, Gard C, Kerlikowske K. Benign breast disease, mammographic breast density and the risk of breast cancer. J Clin Oncol. 2015;33(28):3137-3143.
5. Tyrer J, Duff SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Statist. Med. 2004;23(7):1111-1130.
6. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879-1886.
7. Rosner B, Glynn R, Tamimi R, et al. Breast cancer risk prediction with heterogeneous risk profiles according to breast cancer tumor markers. Am J Epidemiol. 2013;178(2):296-308.
8. Chlebowski RT, Anderson GL, Lane DS, et al. Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst. 2007;99(22):1695-1705.
9. Barnes B, Steindorf K, Hein R, Flesch-Janys D, Chang-Claude J. Population attributable risk of invasive postmenopausal breast cancer and breast cancer subtypes for modifiable and non-modifiable risk factors. Cancer Epidemiol. 2011;35(4):345-352.
10. Visscher D, Frost M, Hartmann L, et al. Clinicopathologic features of breast cancers that develop in women with previous benign breast disease. Cancer. 2016;122(3):378-385.
11. Antoni S, Sasco A, dos Santos Silva I, McCormack V. Is mammographic density differentially associated with breast cancer according to receptor status? A meta-analysis. Breast Cancer Res Treat. 2013;137(2):337-347.
12. Ghosh K, Brandt K, Sellers T, et al. Association of mammographic density with the pathology of subsequent breast cancer among postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2008;17(4):872-879.
13. Aiello E, Buist D, White E, Porter P. Association between mammographic breast density and breast cancer tumor characteristics. Cancer Epidemiol Biomarkers Prev. 2005;14(3):662-668.
14. Ziv E, Tice J, Smith-Bindman R, Shepherd J, Cummings S, Kerlikowske K. Mammographic density and estrogen receptor status of breast cancer. Cancer Epidemiol Biomarkers Prev. 2004;13(12):2090-2095.
15. Yang WT, Dryden M, Broglio K, et al. Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. Breast Cancer Res Treat. 2008;111(3):405-410.
16. Chen JH, Hsu F, Shih H, et al. Does breast density show difference in patients with estrogen receptor-positive and estrogen receptor-negative breast cancer measured on MRI? Ann Oncol. 2009;20(8):1447-1449.
17. Pollán M, Ascunce N, Ederra M, et al. Mammographic density and risk of breast cancer according to tumor characteristics and mode of detection: A Spanish population-based case-control study. Breast Cancer Res. 2013;15(1): R9.
18. Ding J, Warren R, Girling A, Thompson D, Easton D. Mammographic density, estrogen receptor status and other breast cancer tumor characteristics. Breast J 2010;16(3):279-289.
19. Conroy S, Pagano I, Kolonel L, Maskarinec G. Mammographic density and hormone receptor expression in breast cancer: The Multiethnic Cohort Study. Cancer Epidemiol. 2011;35(5):448-452.
20. Eriksson L, Hall P, Czene K, et al. Mammographic density and molecular subtypes of breast cancer. Br J Cancer. 2012;107(1):18-23.
21. Bertrand K, Tamimi R, Scott C, et al Mammographic density and risk of breast cancer by age and tumor characteristics. Breast Cancer Res. 2013;15(6):R104.
22. Kerlikowske K, Walker R, Miglioretti D, Desai A, Ballard-Barbash R, Buist D. Obesity, mammography use and accuracy, and advanced breast cancer risk. J Natl Cancer Inst. 2008;100(23):1724-1733.
23. Bao P, Shu X, Gao Y, et al. Association of hormone-related characteristics and breast cancer risk by estrogen receptor/progesterone receptor status in the Shanghai Breast Cancer Study. Am J Epidemiol. 2011;174(6):661-671.
24. Neuhouser M, Aragaki A, Prentice R, et al. Overweight, obesity, and postmenopausal invasive breast cancer risk: A secondary analysis of the Women's Health Initiative Randomized Clinical Trials. Jama Oncol. 2015;1(5):611-621.
25. Ritte R, Lukanova A, Berrino F, et al. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: A large prospective cohort study. Breast Cancer Res. 2012;14(3):R76.
26. Harris H, Willett W, Terry K, Michels K. Body fat distribution and risk of premenopausal breast cancer in the nurses' health study II. J Natl Cancer Inst. 2011;103(3):273-278.
27. Ballard-Barbash R, Taplin SH, Yankaskas BC, et al. Breast Cancer Surveillance Consortium: A national mammography screening and outcomes database. Am J Roetengol. 1997;169(4):1001-1008.
28. Sickles E, Miglioretti D, Ballard-Barbash R, et al. Performance benchmarks for diagnostic mammography. Radiology. 2005;235(3):775-790.
29. Ahn J, Schatzkin A, Lacey JV Jr, et al. Adiposity, adult weight change, and postmenopausal breast cancer risk. Arch Intern Med. 2007;167(19): 2091-2102.
30. Kerlikowske K, Miglioretti D, Ballard-Barbash R, et al. Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol. 2003;21(23):4314-4321.
31. Kerlikowske K, Miglioretti D, Buist D, Walker R, Carney P. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst. 2007;99(17): 1335-1339.
32. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med. 1998;158(17):1855-1867.
33. Dupont W, Page D. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312(3):146-151.
34. Page D, Dupont W, Rogers L, et al. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer. 1985;55(11):2698-2708.
35. Page D, Schuyler P, Dupont W, et al. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: A retrospective cohort study. Lancet. 2003; 361(9352):125-129.
36. Sickles E, D'Orsi CJ, Bassett LW, et al. ACR BI-RADS Mammography. Reston, VA: 2013.
37. Zheng Y, Heagerty P. Partly conditional survival models for longitudinal data. Biometrics. 2005;61(2):379-391.
38. Lee E, Wei L, Amato D. Cox-Type Regression Analysis for Large Numbers of Small Groups of Correlated Failure Time Observations. The Netherlands: Kluwer Academic Publishers; 1992.
39. Lagakos SW. A covariate model for partially censored data subject to competing causes of failure. J Royal Stat Soc Series C (Appl Stat). 1978;27(3):235-241.
40. Amadou A, Hainaut P, Romieu I. Role of obesity in the risk of breast cancer: Lessons from anthropometry. J Oncol. 2013;906495.
41. Colditz G, Bohlke K. Priorities for the primary prevention of breast cancer. CA Cancer J Clin. 2014;64(3):186-194.
42. Renehan A, Roberts D, Dive C. Obesity and cancer: Pathophysiological and biological mechanisms. Arch Physiol Biochem. 2008;114(1):71-83.
43. Pierobon M, Frankenfeld CL. Obesity as a risk factor for triple-negative breast cancers: A systematic review and meta-analysis. Breast Cancer Res Treat. 2013; 137(1):307-314.
44. Harvie M, Howell A, Vierkant RA, et al. Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev. 2005;14(3): 656-661.
45. Cuzick J, Sestak I, Cawthorn S, et al. Tamoxifen for prevention of breast cancer: Extended longterm follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015;16(1):67-75.
46. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999;281(23): 2189-2197.
47. Key TJ, Appleby PN, Reeves GK et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003; 95(16):1218-1226.
48. Dyrstad SW, Yan Y, Fowler AM, Colditz GA. Breast cancer risk associated with benign breast disease: Systematic review and meta-analysis. Breast Cancer Res Treat. 2015;149(3):569-575.
49. Tan-Chiu E, Wang J, Costantino J, et al. Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. J Natl Cancer Inst. 2003;95(4): 302-307.
50. Khan SA, Rogers MA, Khurana KK, Meguid MM, Numann PJ. Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst. 1998;90(1):37-42.
51. Boyd NF, Dite G, Stone J, et al. Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med. 2002;347(12):886-894.
52. Ziv E, Shepherd J, Smith-Bindman R, Kerlikowske K. Mammographic breast density and family history of breast cancer. J Natl Cancer Inst. 2003;95(7): 556-558.
53. Crest AB, Aiello EJ, Anderson ML, Buist DS. Varying levels of family history of breast cancer in relation to mammographic breast density (United States). Cancer Causes Control. 2006;17(6):843-850.
54. Kennedy SR, Loeb LA, Herr AJ. Somatic mutations in aging, cancer and neurodegeneration. Mech Ageing Dev. 2012;133(4):118-126.
55. Tomasetti C, Vogelstein B, Parmigiani G. Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. Proc Natl Acad Sci U S A. 2013;110(6):1999-2004.
56. Dunning A, Michailidou, K, Kuchenbaecker, KB, et al. Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nat Genet. 2016;48(4):374-386.
57. Fejerman L, Ahmadiyeh N, Hu D, et al. Genome-wide association study of breast cancer in Latinas identifies novel protective variants on 6q25. Nat Commun. 2014;5:5260.
58. Niedhammer I, Bugel I, Goldberg M, Leclere A. Validity of self-reported weight and height in the French Gazel cohort. Int J Obesity. 2000;24(9):1111-1118.
59. Stevens J, Keil JE, Waid R, Gazes PD. Accuracy of current 4-year and 28-year self-reported body weight in an elderly population. Am J Epidemiol. 1990; 132(6):1156-1163.
60. Chlebowski RT, Anderson GL, Aragaki AK, Prentice R. Breast cancer and menopausal hormone therapy by race/ethnicity and body mass index. J Natl Cancer Inst. 2015;108(2):XXX-XXX.
61. Bodian CA, Perzin KH, Lattes R, Hoffmann P. Reproducibility and validity of pathologic classifications of benign breast disease and implications for clinical applications. Cancer. 1993;71(12):3908-3913.
62. Jain RK, Mehta R, Dimitrov R, et al. Atypical ductal hyperplasia: Interobserver and intraobserver variability. Mod Pathol. 2011;24(7):917-923.
63. Masood S, Rosa M. Borderline breast lesions: Diagnostic challenges and clinical implications. Adv Anat Pathol. 2011;18(3):190-198.
64. Rosai J. Borderline epithelial lesions of the breast. Am J Surg Pathol. 1991;15(3): 209-221.
65. Sidawy MK, Stoler MH, Frable WJ, et al. Interobserver variability in the classification of proliferative breast lesions by fine-needle aspiration: Results of the Papanicolaou Society of Cytopathology Study. Diagn Cytopathol. 1998; 18(2):150-165.
66. Sloane JP, Ellman R, Anderson TJ, et al. Consistency of histopathological reporting of breast lesions detected by screening: Findings of the U.K. National External Quality Assessment (EQA) Scheme. U. K. National Coordinating Group for Breast Screening Pathology. Eur J Cancer. 1994;30A(10):1414-1419.